Table 2. Comparison of pharmacokinetic parameters of dalbavancin, oritavancin, telavancin, and vancomycin^1,4,5,6,43.

	Dalbavancin 1,000 mg (IV; single dose)	Oritavancin	Vancomycin 1,000 mg (IV; single dose)	Telavancin 10 mg/kg (IV; single dose)
Cmax	287 mcg/mL	138 mcg/mL	63 mcg/mL	93.6 mcg/mL
Tmax	NA	Immediately following a 3-h infusion	Immediately following a 60-min infusion	Immediately following a 60-min infusion
Half-life	346 h	393 h	4 to 6 h	8 h
AUC0-inf nity	23,443 mg•h/L	2,800 mcg•h/mL	—	747 mcg•h/mL
Clearance	0.0513 L/h	0.456 L/h	0.058 L/h/kg	13.9 mL/h/kg
Volume of distribution	NA	5.88 L (central compartment); 14.8 L (V2); 90 L (V3)	0.864 L/kg	145 mL/kg
Protein binding	93%	85% to 90%	55%	90%
Metabolism	No apparent metabolism	No apparent metabolism	No apparent metabolism	No apparent metabolism
Elimination	Urine: 33% unchanged for dalbavancin, 12% for hydroxy-dalbavancin 42 days postdose Feces: 20%, 70 days postdose	Unchanged in urine and feces	Urine: 75% excreted over 24 h	Urine: 76% Feces: < 1%

Note: AUC = area under the curve; NA = not available in product labeling.